Premium
Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B
Author(s) -
Chan H. L.Y.,
Wong V. W.S.,
Chim A. M.L.,
Chan H.Y.,
Wong G. L.H.,
Sung J. J.Y.
Publication year - 2010
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2010.04474.x
Subject(s) - medicine , hbsag , seroconversion , hepatitis b virus , hepatitis b , antigen , gastroenterology , immunology , lamivudine , virus
Aliment Pharmacol Ther 2010; 32: 1323–1331 Summary Background On‐treatment predictors of response to peginterferon can guide individualization of therapy in chronic hepatitis B virus infection. Aim To investigate the use of serum hepatitis B surface antigen quantification to predict sustained response. Methods Hepatitis B e antigen‐positive chronic hepatitis B patients who received peginterferon for 32–48 weeks with or without lamivudine combination were studied. Sustained response was defined as hepatitis B e antigen seroconversion and chronic hepatitis B virus DNA <10 000 copies/mL until 12 months post‐treatment. Results Twenty‐one of 92 (23%) patients achieved sustained response. At month 6, the area under receiver operating characteristics curve for hepatitis B surface antigen to predict sustained response was 0.77 (95% confidence interval 0.65–0.89, P < 0.001). An hepatitis B surface antigen cutoff at 300 IU/mL at month 6 could give the maximum combination of sensitivity (62%) and specificity (89%) to predict sustained response. Nine of 21 (43%) sustained responders vs. 9 of 71 (13%) nonsustained responders had >1 log hepatitis B surface antigen reduction at month 6 ( P < 0.001). Combined hepatitis B surface antigen ≤300 IU/mL and >1 log reduction at month 6 had sensitivity, specificity, positive and negative predictive values of 43%, 96%, 75% and 85% to predict sustained response, respectively. Conclusion On‐treatment serum hepatitis B surface antigen can predict response to peginterferon therapy in chronic hepatitis B.